Valley National Advisers Inc. Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Valley National Advisers Inc. trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,239 shares of the biopharmaceutical company’s stock after selling 41 shares during the quarter. Valley National Advisers Inc.’s holdings in Regeneron Pharmaceuticals were worth $882,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in REGN. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $49,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $672.98 on Friday. The company has a market cap of $73.95 billion, a P/E ratio of 16.65, a PEG ratio of 1.62 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a one year low of $666.25 and a one year high of $1,211.20. The business’s 50-day simple moving average is $720.81 and its 200 day simple moving average is $922.87. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Analysts Set New Price Targets

REGN has been the subject of several analyst reports. Truist Financial cut their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, December 17th. Citigroup decreased their price target on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $1,004.57.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.